In the latest D2C news India, Mumbai-based Direct-to-consumer India healthcare platform Truemeds has secured a landmark $85 million Series C funding round, positioning itself among the top funded D2C brands in India’s healthcare ecosystem for 2025. The round, completed in two tranches, was led by Accel and Peak XV Partners, with active participation from WestBridge Capital and Info Edge Ventures.
This infusion of growth capital marks a pivotal moment in the Indian D2C updates landscape, signaling heightened investor confidence in VC-backed D2C brands within the healthcare and wellness sector. The company has ambitious D2C expansion plans—including the establishment of new fulfillment centers in non-metro regions, scaling its engineering and product divisions, and opening a new Bengaluru office. With these moves, Truemeds aims to triple its national penetration while introducing new D2C product launches, most notably in diagnostics, over the next two to four months.
Building a Scalable Direct-to-Consumer Healthcare Brand
Founded in 2019 by Akshat Nayyar and Dr. Kunal Wani, Truemeds operates on a D2C business model India that focuses on providing clinically equivalent alternatives to branded medicines. The approach allows patients—particularly those managing chronic conditions like diabetes, hypertension, and cardiovascular diseases—to save 50–70% on their monthly medication expenses.
With a robust D2C supply chain innovation in place, the platform currently serves all major Indian cities, engaging with over 600 doctors daily. The team has grown to more than 3,000 employees, including a 250-member head office, underscoring the brand’s operational scale and efficiency.
Technology, AI, and Omnichannel Healthcare
In line with latest D2C startups leveraging technology, Truemeds is investing heavily in AI- and ML-powered tools to enhance product curation, streamline patient journeys, and improve demand forecasting. This omnichannel D2C strategy ensures that the brand maintains strong consumer engagement both online and offline, a model increasingly embraced by fastest-growing D2C brands in India.
The launch of its iOS app expands digital accessibility, while the upcoming pilot of diagnostic services in four cities reflects the brand’s transition into a full-stack D2C wellness startup. These initiatives are designed to deepen patient trust and broaden the scope of care beyond pharmaceuticals.
Financial Momentum and Investor Confidence
According to D2C funding news tracker TheKredible, Truemeds has now raised over $110 million to date. FY24 saw its revenue double to ₹315 crore, while losses narrowed by 9% to ₹61 crore—clear evidence of D2C revenue growth backed by disciplined scaling.
These results, combined with strong investor participation in its Series C funding India round, place Truemeds in the league of best performing D2C brands FY25, competing with established players like PharmEasy and Tata 1mg in the D2C ecosystem India.
Shaping the Future of Healthcare in the D2C Industry News Landscape
As the latest D2C startups continue to disrupt traditional healthcare delivery, Truemeds is setting an example of how D2C brand building stories can blend affordability, technology, and scalability. With its expanding footprint, advanced tech infrastructure, and planned entry into diagnostics, the company could be a strong candidate for D2C IPO news in the coming years.
In an industry ripe for transformation, Truemeds is more than just a healthcare service—it is a blueprint for sustainable D2C brands in India’s healthcare sector. By owning its supply chain, focusing on patient outcomes, and strategically deploying capital, it is redefining D2C business India in a high-impact category.
With its Series C funding round complete, Truemeds is poised to scale aggressively, innovate continually, and potentially emerge as one of India’s most influential healthcare brands on the D2C market trends 2025 horizon.
